<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31666">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757418</url>
  </required_header>
  <id_info>
    <org_study_id>7R01FD003447-03</org_study_id>
    <secondary_id>FD-R-003447-01-A1</secondary_id>
    <nct_id>NCT01757418</nct_id>
    <nct_alias>NCT00644865</nct_alias>
  </id_info>
  <brief_title>Intravenous Gammaglobulin for Sickle Cell Pain Crises</brief_title>
  <official_title>Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine of Yeshiva University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein College of Medicine of Yeshiva University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intravenous immune globulin is safe and
      effective in the acute treatment of pain crises in sickle cell disease.

      Funding Source: Food and Drug Administration (FDA), Office of Orphan Products Development
      (OOPD)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Duration of pain crisis</measure>
    <time_frame>Number of days from study drug infusion to end of crisis, average 4 days and maximum 30days</time_frame>
    <safety_issue>No</safety_issue>
    <description>End of crisis defined as either 1) Pain score consistently ≤ 5 (on the visual analog or Wong-Baker FACES scale) AND off of IV opioids or 2) Hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total opioid use in equivalent of mg of IV morphine</measure>
    <time_frame>From study drug infusion to end of crisis, average 4 days and maximum 30days</time_frame>
    <safety_issue>No</safety_issue>
    <description>End of crisis defined as either: 1)Pain score consistently ≤ 5 (on the visual analog or Wong-Baker FACES scale AND off of IV opioids or 2) Hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Immune Globulin Intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An equivalent volume (weight-based)of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Globulin Intravenous</intervention_name>
    <description>A single dose of intravenous immune globulin or saline placebo administered within 18 hours of hospital presentation. The current maximum dose planned is 800 mg/kg.</description>
    <arm_group_label>Immune Globulin Intravenous</arm_group_label>
    <other_name>GAMUNEX (Talecris Biotherapeutics)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented diagnosis of sickle cell disease (SS or S-β thalassemia genotype)

          -  Age 12-65 years

          -  Uncomplicated acute pain episode requiring hospital admission and parenteral
             narcotics

        Exclusion Criteria:

          -  Increased stroke risk as assessed by transcranial Doppler or magnetic resonance
             imaging (all subjects undergo testing)

          -  Concomitant acute process, including fever &gt; 38.5° C with clinical suspicion of
             infection

          -  Increased ALT &gt; 2X ULN

          -  Serum creatinine ≥1.3 mg/dL, &gt;300 mg/dL protein in spot urinalysis, or known
             condition associated with renal dysfunction

          -  Hb &gt; 10 g/dL and Hct &gt; 30%

          -  Known IgA deficiency or known allergy to gamma globulin

          -  Pregnancy or breastfeeding

          -  Vaccination with a live attenuated virus in the preceding 6 weeks

          -  Documented history of illicit (eg. heroin, cocaine) drug abuse or drug-seeking
             behavior

          -  Current participation in another investigational drug study

          -  Current treatment with chronic transfusion

          -  Prior thromboses or current estrogen use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepa G Manwani, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine of Yeshiva University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepa G Manwani, M.D</last_name>
    <phone>718-741-2342</phone>
    <email>dmanwani@montefiore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Ireland</last_name>
    <phone>718-741-2401</phone>
    <email>kireland@montefiore.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa G Manwani, MD</last_name>
      <phone>718-741-2342</phone>
      <email>dmanwani@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Deepa G Manwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008 Jan 15;111(2):915-23. Epub 2007 Oct 11.</citation>
    <PMID>17932253</PMID>
  </reference>
  <reference>
    <citation>Turhan A, Jenab P, Bruhns P, Ravetch JV, Coller BS, Frenette PS. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood. 2004 Mar 15;103(6):2397-400. Epub 2003 Nov 20.</citation>
    <PMID>14630831</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine of Yeshiva University</investigator_affiliation>
    <investigator_full_name>Deepa Manwani</investigator_full_name>
    <investigator_title>Director, Sickle Cell Disease Program, Children's Hospital at Montefiore</investigator_title>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Pain</keyword>
  <keyword>Immune Globulin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gamma-Globulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
